Day One
Wednesday October 11, 2017
Day Two
Thursday October 12, 2017
07.45 Registration & Coffee
08.45 Chairman’s Opening Remarks
09.00 Opening Keynote Panel Discussion: A Therapeutic Revolution in Dermatology – Bridging the Gaps & Opportunities
Synopsis
• Addressing the evolving landscape, growing interest and developments in the
dermatology drug development space
• Analyzing the paradigm shift from topical to systemic treatment approaches – tacklingsymptoms vs. causes
• Unmet needs – evaluating the ROI of drug development for rare dermatological conditions
• Outlining where we are and where we are going – important learnings to date and perspectives on future directions
Optimizing Discovery & Preclinical Development in Dermatology
09.45 Precision Medicine in Dermatology – Revolutionizing R&D & Providing Optimal Treatment for Patients
Synopsis
• Assessing how biomarkers provide a unique opportunity to improve disease
understanding: Identifying distinct subtypes (different presentations and different response to treatment), unique disease signatures and early changes in biomarker profiles
• Exploring how early response prediction can reduce late stage attrition
• 2020 – the era of biologics
• Applying in-depth disease and pathway understanding to identify new biologics targets
• Addressing single gen orphan diseases with biologics
• Applying biomarkers to support precision medicine
• Creating the win-win for the Four Ps (Patient, Physician, Payer, Pharma) with Precision Medicine
10.15 Morning Refreshments & Speed Networking
11.45 Translational Research in Dermatology – Setting the Course for Successful/Accelerated Clinical Development
Synopsis
• Exploring how to match the right mechanism with the right indication
• Accelerating clinical development by implementing PD in FIH studies
• Exploring PK-PD for indication expansion
12.15 Skin Biology – A Valuable Tool for the Innovation & Development of Novel Therapeutic Alternatives in Dermatology
Synopsis
- Introducing EnDev Laboratories and the Skin Biology capabilities
- Reviewing different in vivo/ex vivo/in vitro skin models available
- Describing the pre-clinical strategy to de-risk dermal drug development
- Presenting case studies supporting the use of skin biology for innovation and drug development
12.45 Lunch & Networking
Advancing Topical & Small Molecule Drug Development
13.45 Addressing the Innovation Gap in Topical Dermatology Drug Development
Synopsis
• Analyzing the revolution in how moderate to severe dermatologic diseases (e.g., psoriasis
and AD) are now treated in a targeted way with the biologics
• Looking at the innovation gap in topical drug development with many patients still primarily using topical steroids
• Describing the need for a novel targeted topical approach to fill the innovation gap in treatment for the mild to moderate (80-90%) patient population with dermatologic diseases
• Modifying potent small molecules that address key immune targets of psoriasis and atopic dermatitis with a “Topical by Design” approach
• Exploring how “Topical by Design” also results in a favorable safety profile with Low Systemic Exposure (LSE)
14.15 Key considerations in designing topical formulations
Synopsis
• Exploring Target Product Profiles in dermatology applications
• Discussing the latest advances in formulation, analytical and process development technologies
• Analyzing formulation selection criteria
14.45 Targeting Diseases Using Topical Treatments with Spherical Nucleic Acids
Synopsis
• Treating dermatological diseases locally using topically applied drugs – analyzing the Exicure approach
• Exploring Spherical Nucleic Acids – an innovative approach to treating patients using underlying biology by targeting a disease at its genetic source
• Analyzing early clinical data and the shown success using this approach via a TNF pathway in patients with psoriasis
• Tackling other diseases with known genetic drivers
15.15 Innovations to Mitigate Risk in Topical Formulation Development
Synopsis
- Trends in topical and transdermal drug development
- Innovations impacting the trends
- Benefits innovations have brought to topical dermatological medicines development
15.25 Afternoon Refreshments & Networking
15.55 Innovation in Oral Immunomodulators for the Treatment of Psoriasis & Other Dermatological Conditions
Synopsis
• Overviewing Prurisol: A new small molecule under investigation for the treatment of psoriasis
• Exploring HDP Mimetics: Understanding the mechanism of action of endogenous host defence peptides (HDPs) as enhancers of immunomodulatory functions
• Analyzing Brilacidin as a novel small molecule for the treatment of bacterial infections, with successful Phase II b clinical trial results for acute bacterial skin and skin structure infection (ABSSSI)
16.25 Panel Discussion: Debating the Therapeutic Developments in Topicals
Synopsis
• Taking risks in early stages to develop new and innovative topicals
• Addressing the big pharma vs. smaller biotech paradigms and perspectives
• Analyzing the next steps in developing increasingly efficient dermatological topical treatments
